Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer by Argiris Athanassios, Karamouzis Michalis V, Gooding William E, Branstetter Barton F, Zhong Shilong, Raez Luis E, Savvides Panayiotis, Romkes Marjorie in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011).

[PMID: 21343546] PubMed


We hypothesized that bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of the head and neck (SCCHN).

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Rx Annotations

No dosing information annotated.